Physician profile
Oliver Lee
NPI 1891292736
$6,145.55
in general payments reported to CMS, 2019-2025
24 companies · $2,567 in 2025
The $2,567 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $1,294 · 2024: $2,153 · 2025: $2,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,689 · Consulting Fee: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,688.97 |
| Consulting Fee | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $675.36 | 2024-2025 | Tremfya, Rybrevant, Carvykti |
| Amgen INC. | $648.24 | 2023-2025 | Repatha, Amjevita, Blincyto |
| Abbvie INC. | $561.25 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $471.81 | 2023-2025 | Ajovy, Austedo, Uzedy |
| Fresenius Kabi USA, LLC | $370.86 | 2023-2025 | Kabiven, Stimufend, Smoflipid |
| Getinge USA Sales, LLC | $325.00 | 2024 | Flow-I C40 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.85 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.59 | 2025 | Xifaxan |
| Novo Nordisk INC | $248.90 | 2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.33 | 2024 | Imfinzi, Calquence |
| Eisai INC. | $241.89 | 2023-2025 | |
| Glaxosmithkline, LLC. | $230.09 | 2023 | |
| Biogen, INC. | $195.17 | 2023-2025 | Skyclarys, Tysabri |
| Regeneron Healthcare Solutions, INC. | $184.78 | 2025 | Libtayo |
| Janssen Pharmaceuticals, INC | $150.00 | 2024 | Invega Sustenna, Invega |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $149.07 | 2024 | Terlivaz |
| Cequr Corporation | $148.28 | 2023 | Cequr Simplicity |
| Kyowa Kirin, INC. | $137.20 | 2024 | Nourianz |
| Avanos Medical | $131.58 | 2022 | |
| Astellas Pharma US INC | $124.69 | 2025 | Cresemba |
| Genzyme Corporation | $118.80 | 2024 | |
| Jazz Pharmaceuticals INC. | $117.64 | 2025 | |
| Merck Sharp & Dohme LLC | $106.31 | 2023-2024 | Verquvo, Bridion |
| Cook Medical LLC | $42.86 | 2025 | Hemospray |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.